US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
JPH021556A
(en)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
Hybrid antibody and production thereof
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
DE4118120A1
(en)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
CZ287296B6
(en)
|
1992-01-23 |
2000-10-11 |
Merck Patent Gmbh |
Antibody construct and structural kit for selective preparation thereof
|
EP0625200B1
(en)
|
1992-02-06 |
2005-05-11 |
Chiron Corporation |
Biosynthetic binding protein for cancer marker
|
ATE165113T1
(en)
|
1992-05-08 |
1998-05-15 |
Creative Biomolecules Inc |
MULTI-VALUE CHIMERIC PROTEINS ANALOGUE AND METHOD FOR THE APPLICATION THEREOF
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
EP0672068A4
(en)
|
1992-09-25 |
1997-02-26 |
Commw Scient Ind Res Org |
Target binding polypeptide.
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
ATE199392T1
(en)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
JP3659261B2
(en)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
Targeted heterojunction of a recombinant protein to a multifunctional complex
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
CA2222055A1
(en)
|
1995-05-23 |
1996-11-28 |
Morphosys Gesellschaft Fur Proteinoptimierung Mbh |
Multimeric proteins
|
BR9606706A
(en)
|
1995-10-16 |
1999-04-06 |
Unilever Nv |
Bispecific or bivalent antibody fragment analog use process to produce the same
|
ES2225961T3
(en)
|
1996-04-04 |
2005-03-16 |
Unilever N.V. |
MULTIVALLY AND MULTI SPECIFIC ANTIGEN UNION PROTEIN.
|
JP2002505574A
(en)
|
1997-04-30 |
2002-02-19 |
エンゾン,インコーポレイテッド |
Polyalkylene oxide-modified single-chain polypeptides
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
WO1998056906A1
(en)
|
1997-06-11 |
1998-12-17 |
Thoegersen Hans Christian |
Trimerising module
|
CN1203178C
(en)
|
1997-10-27 |
2005-05-25 |
尤尼利弗公司 |
Multivalent antigen-binding proteins
|
DE69922159T2
(en)
|
1998-01-23 |
2005-12-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
MULTI-PURPOSE ANTIBODY DERIVATIVES
|
HUP9900956A2
(en)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Single-chain multiple antigen-binding molecules, their preparation and use
|
DE19819846B4
(en)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalent antibody constructs
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
HUP0104693A3
(en)
|
1998-12-16 |
2003-12-29 |
Warner Lambert Co |
Treatment of arthritis with mek inhibitors
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
AU784634B2
(en)
|
1999-11-30 |
2006-05-18 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
EE05450B1
(en)
|
2000-07-19 |
2011-08-15 |
Warner-Lambert Company |
Oxygenated esters of 4-iodophen laminobenzh droxamic acids, their crystalline forms and pharmaceutical compositions and their use
|
CA2417185A1
(en)
|
2000-07-25 |
2002-01-31 |
Shui-On Leung |
Multivalent target binding protein
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
EP2351838A1
(en)
|
2000-10-20 |
2011-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Crosslinking agonistic antibodies
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
AU2002247826A1
(en)
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
US6770622B2
(en)
|
2001-06-08 |
2004-08-03 |
Gary A. Jarvis |
N-terminally truncated galectin-3 for use in treating cancer
|
DK1399484T3
(en)
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Double-specific ligand and its use
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
ES2276735T3
(en)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
SINGLE CHAIN MULTIMERIC FV ANTIBODIES IN TANDEM.
|
AU2002357072A1
(en)
|
2001-12-07 |
2003-06-23 |
Centocor, Inc. |
Pseudo-antibody constructs
|
IL162734A0
(en)
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
PL221491B1
(en)
|
2002-03-08 |
2016-04-29 |
Eisai R&D Man Co |
Macrocyclic compounds useful as pharmaceuticals
|
PL401637A1
(en)
|
2002-03-13 |
2013-05-27 |
Array Biopharma Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
AU2003227504A1
(en)
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
SI2206517T1
(en)
|
2002-07-03 |
2023-12-29 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2318167T3
(en)
|
2002-07-15 |
2009-05-01 |
The Trustees Of Princeton University |
IAP UNION COMPOUNDS.
|
CN1787837A
(en)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
JP4511943B2
(en)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Antibody against PD-1 and use thereof
|
EP1577288B1
(en)
|
2002-12-26 |
2014-07-23 |
Eisai R&D Management Co., Ltd. |
Selective estrogen receptor modulators
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
AU2004232928A1
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
EP1641826A2
(en)
|
2003-06-27 |
2006-04-05 |
Biogen Idec MA Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
WO2005004809A2
(en)
|
2003-07-01 |
2005-01-20 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
PT1704166E
(en)
|
2004-01-07 |
2015-09-04 |
Novartis Vaccines & Diagnostic |
M-csf-specific monoclonal antibody and uses thereof
|
JP2007523061A
(en)
|
2004-01-16 |
2007-08-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
SMAC peptide mimetics and uses thereof
|
MXPA06008095A
(en)
|
2004-01-16 |
2007-03-28 |
Univ Michigan |
Conformationally constrained smac mimetics and the uses thereof.
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
EP1740173A4
(en)
|
2004-03-23 |
2009-05-27 |
Genentech Inc |
Azabicyclo-octane inhibitors of iap
|
EP2253614B1
(en)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitors of IAP
|
ME01480B
(en)
|
2004-06-11 |
2014-04-20 |
Japan Tobacco Inc |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido'2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
|
ES2524449T3
(en)
|
2004-07-02 |
2014-12-09 |
Genentech, Inc. |
IAP inhibitors
|
WO2006010118A2
(en)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
MX2007000490A
(en)
|
2004-07-12 |
2007-06-11 |
Idun Pharmaceuticals Inc |
Tetrapeptide analogs.
|
EP1773766B1
(en)
|
2004-07-15 |
2014-04-02 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
MX2007002856A
(en)
|
2004-09-02 |
2007-09-25 |
Genentech Inc |
Heteromultimeric molecules.
|
ATE536177T1
(en)
|
2004-10-04 |
2011-12-15 |
Univ Minnesota |
CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF
|
CN101146803A
(en)
|
2004-12-20 |
2008-03-19 |
健泰科生物技术公司 |
Pyrrolidine inhibitors of IAP
|
TR201901929T4
(en)
|
2005-02-08 |
2019-03-21 |
Genzyme Corp |
Antibodies to TGFBeta.
|
PT1866339E
(en)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Gitr binding molecules and uses therefor
|
CN101198698B
(en)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
Process for production of polypeptide by regulation of assembly
|
AU2006232920B2
(en)
|
2005-04-06 |
2011-09-29 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
JP5838021B2
(en)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
KR101339628B1
(en)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
NZ564592A
(en)
|
2005-07-01 |
2011-11-25 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
JP4557003B2
(en)
|
2005-07-01 |
2010-10-06 |
株式会社村田製作所 |
MULTILAYER CERAMIC SUBSTRATE, MANUFACTURING METHOD THEREOF, AND COMPOSITE GREEN SHEET FOR PRODUCTION OF MULTILAYER CERAMIC SUBSTRATE
|
WO2007004606A1
(en)
|
2005-07-04 |
2007-01-11 |
Nikon Vision Co., Ltd. |
Distance measuring apparatus
|
CA2618218C
(en)
|
2005-07-21 |
2015-06-30 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of mek
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1757622B1
(en)
|
2005-08-26 |
2009-12-23 |
PLS Design GmbH |
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
JP5102772B2
(en)
|
2005-11-29 |
2012-12-19 |
ザ・ユニバーシティ・オブ・シドニー |
Demibody: Dimerization activation therapeutic agent
|
NZ596494A
(en)
|
2006-01-13 |
2013-07-26 |
Us Gov Nat Inst Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
AU2007215013A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
NZ591252A
(en)
|
2006-03-17 |
2012-06-29 |
Biogen Idec Inc |
Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
|
PT1999154E
(en)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
US8946391B2
(en)
|
2006-03-24 |
2015-02-03 |
The Regents Of The University Of California |
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
HUE035654T2
(en)
|
2006-04-19 |
2018-05-28 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
WO2008011216A2
(en)
|
2006-05-16 |
2008-01-24 |
Pro-Pharmaceuticals, Inc. |
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
ES2469676T3
(en)
|
2006-05-25 |
2014-06-18 |
Bayer Intellectual Property Gmbh |
Dimeric molecular complexes
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
AU2007285763B2
(en)
|
2006-08-18 |
2011-12-15 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
BRPI0714635A2
(en)
|
2006-08-21 |
2013-06-18 |
Genentech Inc |
compounds, pharmaceutical composition, method for inhibiting abnormal cell growth or treating hyperproliferative dysfunction, method for treating an inflammatory disease, and method for treating an autoimmune disease
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
SG176476A1
(en)
|
2006-11-02 |
2011-12-29 |
Daniel J Capon |
Hybrid immunoglobulins with moving parts
|
MY188335A
(en)
|
2006-11-22 |
2021-11-30 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
ATE484505T1
(en)
|
2006-11-23 |
2010-10-15 |
Novartis Ag |
5-SULFANYLMETHYLÄ1,2,4ÜTRIAZOLÄ1,5-AUPYRIMIDINE- - OLDERIVATES AS CXCR2 ANTAGONISTS
|
AU2007324472A1
(en)
|
2006-11-23 |
2008-05-29 |
Novartis Ag |
5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as CXCR2 antagonists
|
CN101541767A
(en)
|
2006-11-23 |
2009-09-23 |
诺瓦提斯公司 |
Pyrimidines and their use as CXCR2 receptor antagonists
|
NZ614857A
(en)
|
2007-03-29 |
2015-04-24 |
Genmab As |
Bispecific antibodies and methods for production thereof
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
NZ598890A
(en)
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP2160401B1
(en)
|
2007-05-11 |
2014-09-24 |
Altor BioScience Corporation |
Fusion molecules and il-15 variants
|
CA2691357C
(en)
|
2007-06-18 |
2014-09-23 |
N.V. Organon |
Antibodies to human programmed death receptor pd-1
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
EP2178914A2
(en)
|
2007-08-15 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
KR101584823B1
(en)
|
2007-09-12 |
2016-01-22 |
제넨테크, 인크. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
MX2010005783A
(en)
|
2007-11-27 |
2010-08-10 |
Ablynx Nv |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
|
BRPI0819693A2
(en)
|
2007-11-30 |
2020-08-18 |
Glaxo Group Limited |
CONSTRUCTION OF ANTIGEN BINDING, METHOD FOR TREATING A PATIENT SUFFERING FROM CANCER OR AN INFLAMMATORY DISEASE, POLYNUCLEOTIDE SEQUENCE, POLYNUCLEOTIDE, HOSTED CELL, TRANSFORMED, EFFECTIVENESS, HUMAN RESOURCE
|
CN101945870B
(en)
|
2007-12-19 |
2012-10-03 |
健泰科生物技术公司 |
5-anilinoimidazopyridines and methods of use
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
WO2009101611A1
(en)
|
2008-02-11 |
2009-08-20 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
MX2010009416A
(en)
|
2008-02-26 |
2010-09-24 |
Novartis Ag |
Heterocyclic compounds as inhibitors of cxcr2.
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
NZ591176A
(en)
|
2008-08-22 |
2012-11-30 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
EP2328920A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
JP2012501670A
(en)
|
2008-09-12 |
2012-01-26 |
アイシス・イノベーション・リミテッド |
PD-1-specific antibodies and uses thereof
|
MX2011003195A
(en)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
|
WO2010063802A1
(en)
|
2008-12-05 |
2010-06-10 |
Novartis Ag |
3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
|
CN104479018B
(en)
|
2008-12-09 |
2018-09-21 |
霍夫曼-拉罗奇有限公司 |
Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
EP2408775B1
(en)
|
2009-03-20 |
2015-06-17 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
|
ES2708124T3
(en)
|
2009-04-27 |
2019-04-08 |
Oncomed Pharm Inc |
Procedure for preparing heteromultimeric molecules
|
TWI445708B
(en)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
IN2015DN02826A
(en)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
KR101573109B1
(en)
|
2009-11-24 |
2015-12-01 |
메디뮨 리미티드 |
Targeted binding agents against b7-h1
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
Simultaneous inhibition of pd-l1/pd-l2
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
RU2625791C2
(en)
|
2010-02-05 |
2017-07-19 |
Хептейрес Терапьютикс Лимитед |
Derivatives of 1,2,4-triazine-4-amine
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
ES2365960B1
(en)
|
2010-03-31 |
2012-06-04 |
Palobiofarma, S.L |
NEW ANTAGONISTS OF ADENOSINE RECEPTORS.
|
SG10201800757TA
(en)
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
WO2011156518A2
(en)
|
2010-06-10 |
2011-12-15 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
HUE040213T2
(en)
|
2010-06-11 |
2019-02-28 |
Kyowa Hakko Kirin Co Ltd |
Anti-tim-3 antibody
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
AU2011328246B2
(en)
|
2010-11-08 |
2016-06-30 |
Ablynx N.V. |
CXCR2 binding polypeptides
|
RU2625034C2
(en)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Antibodies and other molecules binding b7-h1 and pd-1
|
BR112013030958B1
(en)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
ANTIBODY BINDING GROWTH TRANSFORMATION FACTOR BETA, PHARMACEUTICAL COMPOSITION, USES THEREOF, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, AND METHOD FOR PRODUCTION OF AN ANTIBODY
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
UA117220C2
(en)
|
2011-08-01 |
2018-07-10 |
Дженентек, Інк. |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
KR102024955B1
(en)
|
2011-09-02 |
2019-09-24 |
노파르티스 아게 |
Choline salt of an anti-inflammatory substituted cyclobutenedione compound
|
EP3674320A3
(en)
|
2011-10-27 |
2020-08-12 |
Genmab A/S |
Production of heterodimeric proteins
|
HUE051954T2
(en)
|
2011-11-28 |
2021-03-29 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
JO3357B1
(en)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
Imidazopyrrolidinone compounds
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
WO2013179174A1
(en)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Lighting arrangement
|
EP2854843A4
(en)
|
2012-05-31 |
2016-06-01 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind pd-l1
|
UY34887A
(en)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
US9845356B2
(en)
|
2012-08-03 |
2017-12-19 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
|
EP2900061B1
(en)
|
2012-09-17 |
2020-01-22 |
Galectin Therapeutics Inc. |
Method for enhancing specific immunotherapies in cancer treatment
|
CN107892719B
(en)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
Human monoclonal anti-PD-L1 antibodies and methods of use
|
AU2013334610B2
(en)
|
2012-10-24 |
2018-09-13 |
Novartis Ag |
IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
|
AR093984A1
(en)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
|
MA38325B1
(en)
|
2013-02-19 |
2019-03-29 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degradation agents
|
ME03796B
(en)
|
2013-03-15 |
2021-04-20 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 binding proteins
|
US9815897B2
(en)
|
2013-05-02 |
2017-11-14 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (PD-1)
|
CN111423511B
(en)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
Antigen binding proteins that bind to PD-1
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
AR097306A1
(en)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
MODULATION OF TUMOR IMMUNITY
|
TW201605896A
(en)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
GITR antigen binding proteins
|
KR102100419B1
(en)
|
2013-09-13 |
2020-04-14 |
베이진 스위찰랜드 게엠베하 |
Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
|
WO2015061668A1
(en)
|
2013-10-25 |
2015-04-30 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
JP2017509319A
(en)
|
2014-01-15 |
2017-04-06 |
カドモン コーポレイション,リミティド ライアビリティ カンパニー |
Immunomodulator
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
TWI681969B
(en)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
Human antibodies to pd-1
|
TWI680138B
(en)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
Human antibodies to pd-l1
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
EP3988572A1
(en)
|
2014-01-28 |
2022-04-27 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
RU2016137150A
(en)
|
2014-03-13 |
2018-04-18 |
Ф. Хоффманн-Ля Рош Аг |
METHODS AND COMPOSITIONS FOR MODULATION OF MUTANTS OF ESTROGEN RECEPTORS
|
TWI697500B
(en)
|
2014-03-14 |
2020-07-01 |
瑞士商諾華公司 |
Antibody molecules to lag-3 and uses thereof
|
DK3148579T3
(en)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
ANTI-GITR ANTIBODIES AND METHODS OF USING IT
|
AU2015265870B2
(en)
|
2014-05-29 |
2020-07-09 |
Ventana Medical Systems, Inc. |
PD-L1 antibodies and uses thereof
|
KR101923326B1
(en)
|
2014-06-06 |
2018-11-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(en)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
|
CN106604742B
(en)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
Anti- PD-L1 antibody and its purposes as therapeutic agent and diagnosticum
|
JO3663B1
(en)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
Anti-lag3 antibodies and antigen-binding fragments
|
US10463732B2
(en)
|
2014-10-03 |
2019-11-05 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
MA41044A
(en)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
|
CN114920840A
(en)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
Antibody molecules against PD-L1 and uses thereof
|
HUE047784T2
(en)
|
2014-11-06 |
2020-05-28 |
Hoffmann La Roche |
Anti-tim3 antibodies and methods of use
|
US20160129108A1
(en)
|
2014-11-11 |
2016-05-12 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
CA2978892A1
(en)
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
MA41867A
(en)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
|
MX2017015260A
(en)
|
2015-06-03 |
2018-02-19 |
Squibb Bristol Myers Co |
Anti-gitr antibodies for cancer diagnostics.
|
KR20180031728A
(en)
|
2015-07-23 |
2018-03-28 |
인히브릭스 엘피 |
Multivalent and multispecific GITR binding fusion proteins
|
SI3334431T1
(en)
|
2015-08-11 |
2020-01-31 |
Novartis Ag |
5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
|
EP3334758A1
(en)
|
2015-08-12 |
2018-06-20 |
Medimmune Limited |
Gitrl fusion proteins and uses thereof
|
WO2017027646A1
(en)
|
2015-08-13 |
2017-02-16 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
WO2019104075A1
(en)
|
2017-11-21 |
2019-05-31 |
Novartis Ag |
Trispecific binding molecules against tumor-associated antigens and uses thereof
|
KR20200142525A
(en)
|
2018-04-05 |
2020-12-22 |
노파르티스 아게 |
Trispecific binding molecules for cancer and uses thereof
|
PE20210320A1
(en)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
|
KR20210099614A
(en)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Binding molecules for CD3 and uses thereof
|
US11576889B2
(en)
*
|
2019-09-23 |
2023-02-14 |
The Board Of Regents Of The University Of Texas System |
Methods of identifying and treating patients with HIF-2 inhibitor resistance
|
WO2021217508A1
(en)
*
|
2020-04-29 |
2021-11-04 |
Novartis Ag |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE
|